Liraglutide successfully targets fat that can endanger heart health

Researchers at UT Southwestern have reported that the weight-loss drug once-daily liraglutide combined with lifestyle interventions can significant lower visceral fat and ectopic fat that have been associated with risk to heart health in adults who are overweight or have obesity. The findings were featured in the paper, ‘Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial,’ published in The Lancet Diabetes & Endocrinology.

liraglutide

"Our study used the latest imaging technology to evaluate different fat components in the body,” said Dr Parag Joshi, preventive cardiologist, Assistant Professor of Cardiology, and senior author of the study published in The Lancet Diabetes & Endocrinology. “The main finding was a significant decrease in visceral fat in patients without diabetes but who were overweight or had obesity. These results show the potential of liraglutide treatment for significantly lowering the risk of chronic disease in this population.”


Visceral fat is stored within the abdominal cavity around important internal organs, such as the liver, pancreas, and intestines. Ectopic fat is stored in tissues that normally contain small amounts of fat, such as the liver, skeletal muscle, heart, and pancreas.


The 185 study participants were given a once-daily injection of liraglutide over 40 weeks of treatment. The relative effects of liraglutide on fat reduction were two-fold greater in the abdominal tissues and six-fold greater in the liver than seen on overall body weight. The treatment effect was consistent across race/ethnicity and BMI categories, and among those with or without baseline prediabetes. Liraglutide also reduced fasting blood glucose and inflammation in this trial population without diabetes, the majority of whom had normal blood sugar levels at baseline.


In a 2016 study led by UTSW investigators called the Leader trial, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes was lower in those treated with liraglutide than with placebo.


"Our findings help add a possible mechanism for why there is a benefit of liraglutide on cardiovascular outcomes while also showing its benefits in people without diabetes," added Joshi. "Excess visceral fat and ectopic fat are central to the development of type 2 diabetes and cardiovascular disease. It remains challenging to identify those at highest risk, in order to offer them treatment in addition to lifestyle changes such as diet and exercise."